Cite
HARVARD Citation
Berenson, J. et al. (n.d.). A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. American journal of hematology. 92 (5), pp. 460-466. [Online].